Boston Scientific Corporation
BSX rates a BUY because the market is punishing a real 2026 slowdown too aggressively, while the stock already sits 53.0% below its 52-week high despite still growing revenue, expanding margins, and setting up for a cleaner 2027 earnings reset.
The market is pricing BSX like a broken medtech growth story. That is too harsh. The real story is narrower: two important franchises, WATCHMAN and EP, deteriorated faster than management expected, forcing a FY26 guide cut. That deserved a reset. But the current stock price of $51.43, down 53.0% from the $109.50 high and 27.0% below the 200-day average, now embeds a much weaker future than the rest of the business is actually showing.
The case depends first on the distinction between the troubled businesses and the broader portfolio. In Q2 2026, BSX still delivered 7% organic growth, at the high end of guidance, and Interventional Cardiology grew 15%. Management said 75% of revenue is in a base business expected to grow about 6% in 2H26. That matters because it says the company is not relying on a single hero asset anymore. If that broader portfolio keeps compounding, then 2026 looks more like a digestion year than the start of a multi-year decline.
Second, the stock is cheap on the earnings power management still has in hand. Even after the cut, FY26 adjusted EPS is guided to $3.28 to $3.32, which puts the current price at about 15.5x to 15.7x forward earnings. That is a very different setup from the reported 20.9x trailing P/E and is a more relevant lens for a company absorbing a product-cycle reset. On top of that, management expects about $3.8B of FY26 free cash flow and has launched a restructuring targeting ~$500M of run-rate savings exiting 2029, with over half by 2027. If revenue stabilizes, earnings can recover faster than the market expects.
What keeps conviction at Medium instead of High is simple. Management's 2024 confidence around FARAPULSE-led EP strength did not hold, and WATCHMAN's slowdown tied to clinical evidence has damaged the idea that BSX's moat was getting stronger every quarter. This is not a no-risk turnaround. The thesis needs 2 things to work: EP share loss must stop worsening, and the broader franchises must keep offsetting WATCHMAN pressure. If those happen, today's stock is too low. If not, the stock can stay cheap for longer than bulls want.
EP pressure bottoms faster, WATCHMAN comparisons ease, SEISMIQ IVL and other growth platforms scale, and investors underwrite cleaner double-digit EPS growth again.
FY26 marks the reset year, the base business grows around management's expected 6% pace, and savings plus portfolio mix stabilize EPS into 2027.
WATCHMAN stays negative, EP remains flat or worse in 2027, and the market keeps BSX near a de-rated trough multiple despite cost actions.
Quant call aligns with analyst consensus (Strong Buy: 18 buy / 3 hold / 0 sell).
In the short run, the market is a voting machine, but in the long run, it is a weighing machine.
Forward earnings power matters more than the trailing debate here: on management's FY26 adjusted EPS guide of $3.28 to $3.32, the stock trades at roughly 15.5x to 15.7x forward earnings on the current $51.43 price, well below the reported trailing 20.9x and below most large-cap medtech peers. The moat is weaker than it looked in late 2024 because EP and WATCHMAN have both shown they are not immune to clinical evidence shifts and share loss, but the broader portfolio, especially Interventional Cardiology, Endoscopy, and Neuromodulation, still supports a durable multi-platform franchise over the next 3 to 5 years. AI is more an enabler than a disruptor for BSX, helping procedure planning, imaging interpretation, manufacturing, and sales force efficiency, but not creating the kind of software-led upside that would by itself change the valuation. Regulation and technology shifts cut both ways: they can expand procedural adoption, but the current WATCHMAN referral slowdown proves that new evidence and competing technologies can compress growth faster than the market once expected.
- FY26 guidance still calls for 5% to 6% organic revenue growth and $3.28 to $3.32 adjusted EPS, even after the guide cut.
- The stock trades at 20.9x P/E versus a 30.7x peer average and sits 27.0% below its 200-day average of $70.42.
- Management targets ~$500M of run-rate savings exiting 2029, with over half targeted exiting 2027, while FY26 free cash flow is guided to ~$3.8B.
- Q2 2026 organic revenue still grew 7%, at the high end of guidance, with Interventional Cardiology up 15% and strength in DCB, imaging, and complex PCI.
- Management said 75% of revenue is in a base business expected to grow about 6% in 2H26, which limits the damage from WATCHMAN and EP.
- Adjusted operating margin in Q2 was 28.4%, and FY2025 operating margin improved to 17.0% from 15.7%, showing the company is still getting operating leverage despite mix pressure.
- Earnings execution remains solid: BSX has beaten Street EPS in 8 straight quarters, including +3.0%, +1.5%, and +2.4% beats in the first three quarters of 2026.
- Management explicitly cut FY26 because WATCHMAN is now expected to be flat to low-single digits for the year, with 2H down mid- to high-single digits.
- EP growth is deteriorating faster than expected, with management now seeing 2H26 global EP growth flat because of sharper U.S. share loss and high PFA penetration.
- Q2 EBITDA margin was 25.5%, down 530 bps vs Q1, which shows the earnings model is more sensitive to mix and competitive pressure than the market assumed six months ago.
- Leverage is manageable but not light for a medtech name under pressure, at 2.47x debt/EBITDA with $12.6B of total debt and a Financial Health score of 40.
| Metric | Value | Context |
|---|---|---|
| Current price | $51.43 | Reference price for the $66.84 quant target, 30.0% upside |
| Quant price target | $66.84 | Medium confidence, basis earnings_growth_blend |
| FY2025 revenue | $20.1B | 13.9% YoY growth |
| FY2025 EPS | $1.96 | 5.0% YoY growth |
| FY2025 operating margin | 17.0% | Up from 15.7% in the prior year |
| Valuation | P/E 20.9x, P/S 3.65x, P/B 3.07x | P/E below 30.7x peer average, P/S roughly in line with 3.6x peers |
| FY2026 guidance | Organic growth 5% to 6%, adjusted EPS $3.28 to $3.32 | Cut in Q2 because of WATCHMAN and EP pressure |
| Q3 2026 guidance | Organic growth 3% to 5%, adjusted EPS $0.80 to $0.82 | Next near-term test on October 28, 2026 |
| Balance sheet | Debt/Equity 0.51, Debt/EBITDA 2.47x, Total debt $12.6B | Manageable leverage, but not trivial for a company in a reset year |
| Cash generation and capital returns | FCF $1.3B, capex $0.2B, buybacks $2.0B | Repurchases exceeded FY2025 free cash flow |
| Price action | -53.0% vs 52-week high, -27.0% vs 200-day average | Now at $51.43 versus $109.50 52-week high and $70.42 200-day average |
| Earnings track record | 8 straight EPS beats | Most recent beat was $0.86 vs $0.835, or +3.0% |
The biggest risk is that EP share losses and WATCHMAN referral pressure persist into 2027, which would make the new FY26 guide of $3.28 to $3.32 adjusted EPS a stepping stone to another reset rather than a trough.
Q3 2026 earnings on October 28, 2026, when investors will test the new guide against management's 3% to 5% organic growth and $0.80 to $0.82 EPS outlook.
Ownership is crowded but stable, with the top three institutions holding 79.5% and the largest owners including Vanguard, BlackRock, Fidelity, State Street, and Primecap. Short interest is modest at 1.51%, or 22.3M shares, down 21.2%, with only 1.1 days-to-cover, so this is not a classic squeeze setup. Options positioning is supportive rather than explosive, with a positive GEX regime and zero-gamma at $47.35, about 8.14% below spot, suggesting near-term trading support unless fundamentals break again.
Management expects this revenue base to grow about 6% in 2H26, cushioning the WATCHMAN and EP slowdown.
Q2 2026 grew 15%, driven by DCB, imaging, and complex PCI, and is the clearest current growth engine.
These are the pressure points: EP 2H26 global growth flat, WATCHMAN flat to low-single digits FY26 and mid- to high-single digit decline in 2H26.
The current issues are concentrated in the U.S., where management cited sharper EP competitive share movement and slower WATCHMAN referrals.
BSX cut FY26 as WATCHMAN and EP pressure worsens into 2H.
Management's execution record is better than the current stock chart implies, but not as clean as the 2024 narrative suggested. On the positive side, BSX beat Street EPS in 8 straight quarters, and in the 2024 Q3 call management guided FY24 adjusted EPS to $2.45 to $2.47, FY24 operating margin to about 27%, and free cash flow to exceed $2B, while also signaling strong FARAPULSE supply readiness and double-digit 2025 earnings growth ambition. Since then, FY2025 revenue did grow a strong 13.9% to $20.1B, operating margin improved to 17.0% from 15.7%, and 2026 quarterly EPS beats continued. But the 2026 Q2 call is a clear miss versus the earlier confidence around AF solutions and PFA adoption: management now says, "Our guidance reduction is concentrated in 2 areas: First, WATCHMAN... And second, EP," with FY26 organic growth cut to 5% to 6% and adjusted EPS cut to $3.28 to $3.32. Direction has not changed strategically, but credibility is now mixed: BSX still executes the broader machine well, yet management misread the durability of WATCHMAN demand and U.S. EP competitive positioning.
We now expect the second half to be more pressured than we originally anticipated. To that end, we are updating our full year 2026 guidance for organic revenue of 5% to 6% with our full year adjusted EPS of $3.28 to $3.32, representing growth of 7% to 8%.
For the third quarter, we're guiding to organic revenue growth of 3% to 5% and adjusted EPS of $0.80 to $0.82.
Our guidance reduction is concentrated in 2 areas: First, WATCHMAN, where the U.S. market has slowed sharply and unexpectedly, primarily driven by compounding clinical evidence, which has impacted referral patterns. And second, EP, where we did not anticipate the degree of competitive share movement we're now seeing in the U.S. market.
Organic revenue growth was also 7.0% versus our second quarter guidance range of 5% to 7%. Second quarter 2026 adjusted earnings per share of $0.86 grew 15% versus 2025, exceeding the high end of our guidance range of $0.82 to $0.84, primarily driven by favorable discrete tax items.
We now expect to expand full year 2026 adjusted operating margin by 0 to 25 basis points. We anticipate this comprehensive company-wide program will deliver run rate savings of approximately $500 million exiting 2029.
BSX's moat comes from installed physician relationships, broad category coverage across cardiovascular, endoscopy, and neuromodulation, and the regulatory and clinical barriers that make switching slower than in most healthcare markets. That moat is still real, but it is less bulletproof than the market assumed when FARAPULSE momentum was peaking, because the company has now shown visible vulnerability to U.S. EP share loss and to changing WATCHMAN referral patterns tied to clinical evidence. Durability still looks good at the enterprise level, but narrower at the product line level.
Capital deployment has been aggressive. FY2025 free cash flow was $1.3B, capex was just $0.2B, and buybacks ran $2.0B, which means repurchases outpaced current-year FCF and leaned on balance sheet capacity. The positive read is that management is still funding internal programs, restructuring, and targeted external options like MiRus and the expected Penumbra close in 2H26. The caution is that with debt/EBITDA at 2.47x and no dividend, future capital allocation has to favor deleveraging discipline over purely financial support for the stock.
BSX rates a BUY at Medium conviction. The company has real franchise damage in WATCHMAN and EP, and that is why conviction stops short of High. But the stock has already absorbed a severe derating, now trades on a modest forward earnings multiple, and still sits on a broad medtech portfolio that is growing and producing margin support. The setup works if 2026 is the reset year and not the beginning of a longer earnings unwind. A downgrade to HOLD would require another material cut to the $3.28 to $3.32 EPS framework or evidence that the broader 75% base business is no longer holding near 6% growth.
≣ Full research note tap to expand
Executive Summary
BUY, Medium conviction. Rated BUY, Medium conviction. The stock has been hit for legitimate reasons, management cut FY26 on WATCHMAN and EP weakness, but the current setup discounts a lot: BSX trades at 20.9x earnings, below the 30.7x peer average, while still guiding 5% to 6% organic growth, $3.28 to $3.32 adjusted EPS, and about $3.8B of FY26 free cash flow. The key question is not whether 2H26 is weak, it is whether the base business, 75% of revenue, can keep growing about 6% while restructuring and new product ramps rebuild earnings power into 2027.
Investment Thesis
The market is pricing BSX like a broken medtech growth story. That is too harsh. The real story is narrower: two important franchises, WATCHMAN and EP, deteriorated faster than management expected, forcing a FY26 guide cut. That deserved a reset. But the current stock price of $51.43, down 53.0% from the $109.50 high and 27.0% below the 200-day average, now embeds a much weaker future than the rest of the business is actually showing.
The case depends first on the distinction between the troubled businesses and the broader portfolio. In Q2 2026, BSX still delivered 7% organic growth, at the high end of guidance, and Interventional Cardiology grew 15%. Management said 75% of revenue is in a base business expected to grow about 6% in 2H26. That matters because it says the company is not relying on a single hero asset anymore. If that broader portfolio keeps compounding, then 2026 looks more like a digestion year than the start of a multi-year decline.
Second, the stock is cheap on the earnings power management still has in hand. Even after the cut, FY26 adjusted EPS is guided to $3.28 to $3.32, which puts the current price at about 15.5x to 15.7x forward earnings. That is a very different setup from the reported 20.9x trailing P/E and is a more relevant lens for a company absorbing a product-cycle reset. On top of that, management expects about $3.8B of FY26 free cash flow and has launched a restructuring targeting ~$500M of run-rate savings exiting 2029, with over half by 2027. If revenue stabilizes, earnings can recover faster than the market expects.
What keeps conviction at Medium instead of High is simple. Management's 2024 confidence around FARAPULSE-led EP strength did not hold, and WATCHMAN's slowdown tied to clinical evidence has damaged the idea that BSX's moat was getting stronger every quarter. This is not a no-risk turnaround. The thesis needs 2 things to work: EP share loss must stop worsening, and the broader franchises must keep offsetting WATCHMAN pressure. If those happen, today's stock is too low. If not, the stock can stay cheap for longer than bulls want.
Key Metrics
| Metric | Value | Context |
|---|---|---|
| Current price | $51.43 | Reference price for the $66.84 quant target, 30.0% upside |
| Quant price target | $66.84 | Medium confidence, basis earnings_growth_blend |
| FY2025 revenue | $20.1B | 13.9% YoY growth |
| FY2025 EPS | $1.96 | 5.0% YoY growth |
| FY2025 operating margin | 17.0% | Up from 15.7% in the prior year |
| Valuation | P/E 20.9x, P/S 3.65x, P/B 3.07x | P/E below 30.7x peer average, P/S roughly in line with 3.6x peers |
| FY2026 guidance | Organic growth 5% to 6%, adjusted EPS $3.28 to $3.32 | Cut in Q2 because of WATCHMAN and EP pressure |
| Q3 2026 guidance | Organic growth 3% to 5%, adjusted EPS $0.80 to $0.82 | Next near-term test on October 28, 2026 |
| Balance sheet | Debt/Equity 0.51, Debt/EBITDA 2.47x, Total debt $12.6B | Manageable leverage, but not trivial for a company in a reset year |
| Cash generation and capital returns | FCF $1.3B, capex $0.2B, buybacks $2.0B | Repurchases exceeded FY2025 free cash flow |
| Price action | -53.0% vs 52-week high, -27.0% vs 200-day average | Now at $51.43 versus $109.50 52-week high and $70.42 200-day average |
| Earnings track record | 8 straight EPS beats | Most recent beat was $0.86 vs $0.835, or +3.0% |
Financial Strength
The balance sheet is solid enough to support a BUY, but not strong enough to ignore. Leverage at 2.47x debt/EBITDA and $12.6B of debt is acceptable for a scaled medtech platform, especially with a Low overall risk score of 38/100, but it reduces room for error if EP and WATCHMAN stay weak longer than expected. The more encouraging piece is margin structure: FY2025 operating margin improved to 17.0% from 15.7%, Q2 adjusted operating margin held 28.4% despite mix pressure, and the new restructuring program should support a better earnings floor. Cash generation is the swing factor. FY2025 FCF of $1.3B was modest relative to buybacks, but management's FY26 FCF outlook of ~$3.8B implies a much healthier conversion profile if execution holds.
Competitive Position
BSX's moat comes from installed physician relationships, broad category coverage across cardiovascular, endoscopy, and neuromodulation, and the regulatory and clinical barriers that make switching slower than in most healthcare markets. That moat is still real, but it is less bulletproof than the market assumed when FARAPULSE momentum was peaking, because the company has now shown visible vulnerability to U.S. EP share loss and to changing WATCHMAN referral patterns tied to clinical evidence. Durability still looks good at the enterprise level, but narrower at the product line level.
Management & Guidance
Current guidance is clearly more cautious than six quarters ago, and rightly so. Management now expects FY26 organic growth of 5% to 6%, reported growth of 5.5% to 6.5%, adjusted EPS of $3.28 to $3.32, and adjusted operating margin expansion of 0 to 25 bps. The credibility read is mixed but net positive. BSX has consistently beaten quarterly EPS expectations, including a Q2 adjusted EPS result of $0.86 versus the $0.82 to $0.84 guide, but management also admitted its prior view of 2H26 was too optimistic. The key quote matters: "We now expect the second half to be more pressured than we originally anticipated." That lowers confidence in the shape of recovery, but the beat history and the specificity of the revised guide still support taking management's new base case seriously.
Segment Analysis
- Base business (75% of revenue): Management expects this revenue base to grow about 6% in 2H26, cushioning the WATCHMAN and EP slowdown.
- Interventional Cardiology (Not disclosed): Q2 2026 grew 15%, driven by DCB, imaging, and complex PCI, and is the clearest current growth engine.
- Electrophysiology and WATCHMAN (Not disclosed): These are the pressure points: EP 2H26 global growth flat, WATCHMAN flat to low-single digits FY26 and mid- to high-single digit decline in 2H26.
- Geography (Not disclosed): The current issues are concentrated in the U.S., where management cited sharper EP competitive share movement and slower WATCHMAN referrals.
Capital Allocation
Capital deployment has been aggressive. FY2025 free cash flow was $1.3B, capex was just $0.2B, and buybacks ran $2.0B, which means repurchases outpaced current-year FCF and leaned on balance sheet capacity. The positive read is that management is still funding internal programs, restructuring, and targeted external options like MiRus and the expected Penumbra close in 2H26. The caution is that with debt/EBITDA at 2.47x and no dividend, future capital allocation has to favor deleveraging discipline over purely financial support for the stock.
Management Execution & Track Record
Management's execution record is better than the current stock chart implies, but not as clean as the 2024 narrative suggested. On the positive side, BSX beat Street EPS in 8 straight quarters, and in the 2024 Q3 call management guided FY24 adjusted EPS to $2.45 to $2.47, FY24 operating margin to about 27%, and free cash flow to exceed $2B, while also signaling strong FARAPULSE supply readiness and double-digit 2025 earnings growth ambition. Since then, FY2025 revenue did grow a strong 13.9% to $20.1B, operating margin improved to 17.0% from 15.7%, and 2026 quarterly EPS beats continued. But the 2026 Q2 call is a clear miss versus the earlier confidence around AF solutions and PFA adoption: management now says, "Our guidance reduction is concentrated in 2 areas: First, WATCHMAN... And second, EP," with FY26 organic growth cut to 5% to 6% and adjusted EPS cut to $3.28 to $3.32. Direction has not changed strategically, but credibility is now mixed: BSX still executes the broader machine well, yet management misread the durability of WATCHMAN demand and U.S. EP competitive positioning.
Positioning & Flows
Ownership is crowded but stable, with the top three institutions holding 79.5% and the largest owners including Vanguard, BlackRock, Fidelity, State Street, and Primecap. Short interest is modest at 1.51%, or 22.3M shares, down 21.2%, with only 1.1 days-to-cover, so this is not a classic squeeze setup. Options positioning is supportive rather than explosive, with a positive GEX regime and zero-gamma at $47.35, about 8.14% below spot, suggesting near-term trading support unless fundamentals break again.
Bull Case
- Q2 2026 organic revenue still grew 7%, at the high end of guidance, with Interventional Cardiology up 15% and strength in DCB, imaging, and complex PCI.
- Management said 75% of revenue is in a base business expected to grow about 6% in 2H26, which limits the damage from WATCHMAN and EP.
- Adjusted operating margin in Q2 was 28.4%, and FY2025 operating margin improved to 17.0% from 15.7%, showing the company is still getting operating leverage despite mix pressure.
- Earnings execution remains solid: BSX has beaten Street EPS in 8 straight quarters, including +3.0%, +1.5%, and +2.4% beats in the first three quarters of 2026.
Bear Case
- Management explicitly cut FY26 because WATCHMAN is now expected to be flat to low-single digits for the year, with 2H down mid- to high-single digits.
- EP growth is deteriorating faster than expected, with management now seeing 2H26 global EP growth flat because of sharper U.S. share loss and high PFA penetration.
- Q2 EBITDA margin was 25.5%, down 530 bps vs Q1, which shows the earnings model is more sensitive to mix and competitive pressure than the market assumed six months ago.
- Leverage is manageable but not light for a medtech name under pressure, at 2.47x debt/EBITDA with $12.6B of total debt and a Financial Health score of 40.
Valuation & Price Target
Engine price target $66.84 (+30% vs current), Medium confidence.
- P/E Multiple: $85.27 (28% weight)
- PEG (growth-adjusted): $51.71 (20% weight)
- P/S Multiple: $56.53 (20% weight)
- Quality-adjusted: $59.1 (20% weight)
- DCF: $99.81 (4% weight)
This rating aligns with the quant baseline BUY and keeps the same Medium conviction, but for a more selective reason than the model alone implies. The engine's $66.84 target is supported by upside from the current $51.43 price, and the stock's 20.9x P/E is plainly below the 30.7x peer average, though the peer set has wide 5.8x dispersion, which makes pure multiple-based upside less reliable. The decisive support for BUY is the forward setup: management still guides $3.28 to $3.32 EPS and about $3.8B FCF for FY26, while the stock trades at only about 15.5x to 15.7x that earnings base after a 53.0% collapse from the 52-week high. Sell-side consensus is also bullish, but that is low-signal context only; the real issue is whether 2026 is a trough year, and at this valuation the answer is favorable enough to stay constructive.
Risk Assessment
Risk score 38/100 (Low). The biggest risk is that EP share losses and WATCHMAN referral pressure persist into 2027, which would make the new FY26 guide of $3.28 to $3.32 adjusted EPS a stepping stone to another reset rather than a trough.
The Bottom Line
BSX rates a BUY at Medium conviction. The company has real franchise damage in WATCHMAN and EP, and that is why conviction stops short of High. But the stock has already absorbed a severe derating, now trades on a modest forward earnings multiple, and still sits on a broad medtech portfolio that is growing and producing margin support. The setup works if 2026 is the reset year and not the beginning of a longer earnings unwind. A downgrade to HOLD would require another material cut to the $3.28 to $3.32 EPS framework or evidence that the broader 75% base business is no longer holding near 6% growth.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr